张亚南

姓       名： 张亚南

职称职务： 副研究员

电子邮箱：ynzhang@wh.iov.cn

研究方向

（1）甲病毒复制和包装机制研究

（2）新型基因工程疫苗研发等

教育及工作经历

2012.09-2016.06  东北农业大学，生物工程专业，学士

2016.09-2018.06  东北农业大学，生物工程专业，硕士

2018.09-2021.06  中国科学院大学/武汉病毒研究所，微生物学专业，博士

2021.07-2023.07  广州市妇女儿童医疗中心/中国科学院武汉病毒研究所， 联合培 养博士后

2023.07-2023.10  中国科学院武汉病毒研究所，助理研究员

2023.11-至今       中国科学院武汉病毒研究所，副研究员

近五年承担项目

1.国家自然科学基金，青年基金项目，32200132，衣壳蛋白缺失的基孔肯雅病毒包装机制研究，2023年1月-2025年12月，在研，主持；

2.中国博士后科学基金，第72批博后面上项目二等资助，利用甲病毒复制型mRNA肺部靶向递送 hACE2 中和抗体的抗新冠病毒感染通用策略研究，2023年1月-2024年12月，已结题，主持；

3.病毒所青年“突击队”攻关项目，尼帕病毒的新型载体疫苗技术研究，2023年8月-2024年7月，在研，主持；

4.中国科学院特别研究助理资助项目，甲病毒的复制及其包装机制研究2024年1月-2025年12月，在研，主持。

近五年代表性论文

1.   Zhang, Y. N.？, H. Q. Zhang？, G. F. Wang？, Z. R. Zhang？, J. Q. Li？, X. L. Chen, Y. Y. Hu, X. Y. Zeng, Y. J. Shi, J. Wang, Y. H. Li, X. D. Li, C. H. Wang, B. Zhu*, and B. Zhang*. 2023. Intranasal delivery of replicating mRNA encoding hACE2-targeting antibody against SARS-CoV-2 Omicron infection in the hamster, Antiviral Res, 209: 105507.(共同第一作者第一位,IF=5.8)

2.   Zhang, Y. N.？, Z. R. Zhang？, H. Q. Zhang？, N. Li, Q. Y. Zhang, X. D. Li, C. L. Deng, F. Deng, S. Shen, B. Zhu*, and B. Zhang*. 2022. Different pathogenesis of SARS-CoV-2 Omicron variant in wild-type laboratory mice and hamsters, Signal Transduct Target Ther, 7: 62.(共同第一作者第一位,IF=37.2)

3.   Zhang, Y. N., Z. R. Zhang, N. Li, X. R. Pei, X. D. Li, C. L. Deng, H. Q. Ye, and B. Zhang. 2022. High-Titer Self-Propagating Capsidless Chikungunya Virus Generated in Vero Cells as a Strategy for Alphavirus Vaccine Development, J Virol, 96: e0148021 (IF=4.9)

4.   Zhang, Y. N.？, Z. R. Zhang？, H. Q. Zhang？, X. D. Li, J. Q. Li, Q. Y. Zhang, J. Liu, Q. Li, C. L. Deng, Z. L. Shi, Z. M. Yuan, H. Q. Ye, and B. Zhang. 2021. Increased morbidity of obese mice infected with mouse-adapted SARS-CoV-2, Cell Discov, 7: 74. (共同第一作者第一位,IF=21.9 )

5.    Zhang, Y. N., S. Q. Liu, C. L. Deng, Z. M. Yuan, B. Zhang*, X. D. Li*, and H. Q. Ye*. 2021. Development and Characterization of SYBR Green I Based RT-PCR Assay for Detection of Omsk Hemorrhagic Fever Virus, Virol Sin, 36: 1644-47 (IF=4.9)

6.   Zhang, Y. N.？, N. Li？, Q. Y. Zhang？, J. Liu, S. L. Zhan, L. Gao, X. Y. Zeng, F. Yu, H. Q. Zhang, X. D. Li, C. L. Deng, P. Y. Shi, Z. M. Yuan, S. P. Yuan, H. Q. Ye*, and B. Zhang*. 2021. Rational design of West Nile virus vaccine through large replacement of 3' UTR with internal poly(A), EMBO Mol Med, 13: e14108.(共同第一作者第一位，IF=11.4)

7.   Zhang, Y. N.？, X. D. Li？, Z. R. Zhang？, H. Q. Zhang, N. Li, J. Liu, J. Q. Li, H. J. Zhang, Z. J. Wang, S. Shen, Z. L. Shi, H. P. Wei, Z. M. Yuan, H. Q. Ye*, and B. Zhang*. 2020. A mouse model for SARS-CoV-2 infection by exogenous delivery of hACE2 using alphavirus replicon particles, Cell Res, 30: 1046-48.(共同第一作者第一位，IF=39.3)

8.   Zhang, Y. N.？, C. Chen？, C. L. Deng, C. G. Zhang, N. Li, Z. Wang, L. Zhao*, and B. Zhang*. 2020. A novel rabies vaccine based on infectious propagating particles derived from hybrid VEEV-Rabies replicon, EBioMedicine, 56: 102819.(共同第一作者第一位,IF=10.0)

9.    Zhang, Y. N.？, C. L. Deng？, J. Q. Li, N. Li, Q. Y. Zhang, H. Q. Ye, Z. M. Yuan, and B. Zhang*. 2019. Infectious Chikungunya Virus (CHIKV) with a Complete Capsid Deletion: a New Approach for a CHIKV Vaccine, J Virol, 93.(共同第一作者第一位，IF=4.9)

10. Zhang YN﹟, Zhang QY﹟, Li XD﹟, Xiong J, Xiao SQ, Wang Z, Zhang ZR, Deng CL, Yang XL, Wei HP, Yuan ZM, Ye HQ, Zhang B. 2020. Gemcitabine, lycorine and oxysophoridine inhibit novel coronavirus (SARS-CoV-2) in cell culture. Emerg Microbes Infect 2020;9(1):1170-1173.（IF：9.9）

11. Zhang, Z. R.？, Zhang, Y. N.？, X. D. Li？, H. Q. Zhang, S. Q. Xiao, F. Deng, Z. M. Yuan, H. Q. Ye*, and B. Zhang*. 2020. A cell-based large-scale screening of natural compounds for inhibitors of SARS-CoV-2, Signal Transduct Target Ther, 5: 218.(共同第一作者第二位,IF=37.2)

12. Chen, Y.？, Zhang, Y. N.？, R. Yan？, G. Wang？, Y. Zhang, Z. R. Zhang, Y. Li, J. Ou, W. Chu, Z. Liang, Y. Wang, Y. L. Chen, G. Chen, Q. Wang, Q. Zhou, B. Zhang*, and C. Wang*. 2021. ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blocker, Signal Transduct Target Ther, 6: 315.(共同第一作者第二位,IF=37.2)

13. Ou, J. X.？, Zhang, Y. N.？, Y. M Wang？, Z. Zhang, H. P. Wei, J. P. Yu, Q. Wang, G. F. Wang*, B. Zhang*, and C. H*. Wang. 2022. ACE2-Targeting antibody suppresses SARS-CoV-2 Omicron and Delta variants, Signal Transduct Target Ther, 7: 43.(共同第一作者第二位,IF=37.2)

14. Li, Y. Y.？, Zhang, Y. N？., Y. Zhou, Y. Li, J. Xu, Y. B. Ai, L. Xu, X. L. Xiao, B. Zhang, and J. Jin*. 2023. An RBD virus-like particle vaccine for SARS-CoV-2 induces cross-variant antibody responses in mice and macaques, Signal Transduct Target Ther, 8: 173.(共同第一作者第二位,IF=37.2)

15. Zhang, H. Q？., Zhang, Y. N.？, Z. R. Zhang？, X. L. Chen, Y. Y. Hu, Y. J. Shi, J. Wang, C. L. Deng, B. Zhang*, X. D. Li*, and H. Q. Ye*. 2022. An alphavirus replicon particle delivering prefusion-stabilized spike protein provides potent immunoprotection against SARS-CoV-2 Omicron variant, Signal Transduct Target Ther, 7: 390.(共同第一作者第二位,IF=37.2)

16.  Chen, J. J.？, C. L. Huang？, Zhang, Y. N.？, S. Zhang, and M. L. Jin*. 2020. 'Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Pets in Wuhan, China', J Infect, 81: e68-e69.(共同第一作者第三位)

17. Huang, S. C.？, Y. Liu？, Zhang, Y. N.？, R. Zhang, C. J. Zhu, L. H. Fan, G. Pei*, B. Zhang*, and Y. F. Shi*. 2020. Baicalein inhibits SARS-CoV-2/VSV replication with interfering mitochondrial oxidative phosphorylation in a mPTP dependent manner, Signal Transduct Target Ther, 5: 266.(共同第一作者第三位,IF=37.2)

18. Zhang, Z. R.？, H. Q. Zhang？, Zhang, Y. N.？, Q. Y. Zhang, Q. J. Liu, Y. Y. Hu, X. L. Chen, J. Wang, Y. J. Shi, C. L. Deng, P. Gong, B. Zhang*, X. D. Li*, B. Zhu*, and H. Q. Ye*. 2023. Oridonin inhibits SARS-CoV-2 replication by targeting viral proteinase and polymerase, Virol Sin.(在线，共同第一作者第三位,IF=4.9)

19. Li, J. Q.？, Z. R. Zhang？, H. Q. Zhang？, Zhang, Y. N.？, X. Y. Zeng, Q. Y. Zhang, C. L. Deng, X. D. Li, B. Zhang*, and H. Q. Ye*. 2021. Intranasal delivery of replicating mRNA encoding neutralizing antibody against SARS-CoV-2 infection in mice, Signal Transduct Target Ther, 6: 369.(共同第一作者第四位,IF=37.2)